Tine Sylvest Meyhoff

Tine Sylvest Meyhoff

Auto-generated profile, based on publicly available information

Tine Sylvest Meyhoff


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Chest
Verified
Journal Article
Closed access
TMTine Sylvest Meyhoff
Tine Sylvest Meyhoff
MMMorten Hylander Møller
Morten Hylander Møller
PHPeter Buhl Hjortrup
Peter Buhl Hjortrup
MCMaria Cronhjort
Maria Cronhjort
APAnders Perner
Anders Perner
JWJørn Wetterslev
Jørn Wetterslev

5 July 2019 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
TMTine Sylvest Meyhoff
Tine Sylvest Meyhoff
PHPeter Buhl Hjortrup
Peter Buhl Hjortrup
MMMorten Hylander Møller
Morten Hylander Møller
JWJørn Wetterslev
Jørn Wetterslev
TLTheis Lange
Theis Lange
APAnders Perner
Anders Perner

20 September 2021 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
MMMarie Warrer Munch
Marie Warrer Munch
TMTine Sylvest Meyhoff
Tine Sylvest Meyhoff
MHMarie Helleberg
Marie Helleberg
MKMaj‐Brit Nørregaard Kjær
Maj‐Brit Nørregaard Kjær
AGAnders Granholm
Anders Granholm
APAnders Perner
Anders Perner
Background: In the early phase of the pandemic, some guidelines recommended the use of corticosteroids for critically ill patients with COVID‐19, whereas others recommended against the use despite lack of firm evidence of either benefit or harm. In the COVID STEROID trial, we aimed to assess the effects of low‐dose hydrocortisone on patient‐centred outcomes in adults with COVID‐19 and severe hypoxia.Methods: In this multicentre, parallel‐group, placebo‐controlled, blinded, centrally randomised, stratified clinical trial, we randomly assigned adults with confirmed COVID‐19 and severe hypoxia (use of mechanical ventilation or supplementary oxygen with a flow of at least 10 L/min) to either hydrocortisone (200 mg/d) vs a matching placebo for 7 days or until hospital discharge. The primary outcome was the number of days alive without life support at day 28 after randomisation.Results: The trial was terminated early when 30 out of 1000 participants had been enrolled because of external evidence indicating benefit from corticosteroids in severe COVID‐19. At day 28, the median number of days alive without life support in the hydrocortisone vs placebo group were 7 vs 10 (adjusted mean difference: −1.1 days, 95% CI −9.5 to 7.3, P = .79); mortality was 6/16 vs 2/14; and the number of serious adverse reactions 1/16 vs 0/14.Conclusions: In this trial of adults with COVID‐19 and severe hypoxia, we were unable to provide precise estimates of the benefits and harms of hydrocortisone as compared with placebo as only 3% of the planned sample size were enrolled.Trial registration: ClinicalTrials.gov: NCT04348305. European Union Drug Regulation Authorities Clinical Trials (EudraCT) Database: 2020‐001395‐15.

2 May 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
FGFor the Efraim investigators and the Nine-I study group
For the Efraim investigators and the Nine-I study group
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
VLVirginie Lemiale
Virginie Lemiale
PGPierce Geoghegan
Pierce Geoghegan
MMMary Aisling McMahon
Mary Aisling McMahon
EAElie Azoulay
Elie Azoulay
It is unclear whether influenza infection and associated co-infection are associated with patient-important outcomes in critically ill immunocompromised patients with acute respiratory failure. Preplanned secondary analysis of EFRAIM, a prospective cohort study of 68 hospitals in 16 countries. We included 1611 patients aged 18 years or older with non-AIDS-related immunocompromise, who were admitted to the ICU with acute hypoxemic respiratory failure. The main exposure of interest was influenza infection status. The primary outcome of interest was all-cause hospital mortality, and secondary outcomes ICU length of stay (LOS) and 90-day mortality. Influenza infection status was categorized into four groups: patients with influenza alone (n = 95, 5.8%), patients with influenza plus pulmonary co-infection (n = 58, 3.6%), patients with non-influenza pulmonary infection (n = 820, 50.9%), and patients without pulmonary infection (n = 638, 39.6%). Influenza infection status was associated with a requirement for intubation and with LOS in ICU (P < 0.001). Patients with influenza plus co-infection had the highest rates of intubation and longest ICU LOS. On crude analysis, influenza infection status was associated with ICU mortality (P < 0.001) but not hospital mortality (P = 0.09). Patients with influenza plus co-infection and patients with non-influenza infection alone had similar ICU mortality (41% and 37% respectively) that was higher than patients with influenza alone or those without infection (33% and 26% respectively). A propensity score-matched analysis did not show a difference in hospital mortality attributable to influenza infection (OR = 1.01, 95%CI 0.90–1.13, P = 0.85). Age, severity scores, ARDS, and performance status were all associated with ICU, hospital, and 90-day mortality. Category of infectious etiology of respiratory failure (influenza, non-influenza, influenza plus co-infection, and non-infectious) was associated with ICU but not hospital mortality. In a propensity score-matched analysis, influenza infection was not associated with the primary outcome of hospital mortality. Overall, influenza infection alone may not be an independent risk factor for hospital mortality in immunosuppressed patients.

31 March 2022 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
AGAnders Granholm
Anders Granholm
MKMaj-Brit Nørregaard Kjær
Maj-Brit Nørregaard Kjær
MMMarie Warrer Munch
Marie Warrer Munch
SMSheila Nainan Myatra
Sheila Nainan Myatra
BVBharath Kumar Tirupakuzhi Vijayaraghavan
Bharath Kumar Tirupakuzhi Vijayaraghavan
APAnders Perner
Anders Perner
Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference − 4.3%; 99% confidence interval (CI) − 11.7–3.0; relative risk 0.89; 0.72–1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI − 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (− 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.

18 June 2023 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
MKMaj-Brit Nørregaard Kjær
Maj-Brit Nørregaard Kjær
TMTine Sylvest Meyhoff
Tine Sylvest Meyhoff
PSPraleene Sivapalan
Praleene Sivapalan
AGAnders Granholm
Anders Granholm
PHPeter Buhl Hjortrup
Peter Buhl Hjortrup
APAnders Perner
Anders Perner
Purpose To assess long-term outcomes of restrictive versus standard intravenous (IV) fluid therapy in adult intensive care unit (ICU) patients with septic shock included in the European Conservative versus Liberal Approach to Fluid Therapy in Septic Shock in Intensive Care (CLASSIC) trial. Methods We conducted the pre-planned analyses of mortality, health-related quality of life (HRQoL) using EuroQol (EQ)-5D-5L index values and EQ visual analogue scale (VAS), and cognitive function using Mini Montreal Cognitive Assessment (Mini MoCA) test at 1 year. Deceased patients were assigned numerical zero for HRQoL as a state equal to death and zero for cognitive function outcomes as worst possible score, and we used multiple imputation for missing data on HRQoL and cognitive function. Results Among 1554 randomized patients, we obtained 1-year data on mortality in 97.9% of patients, HRQoL in 91.3%, and cognitive function in 86.3%. One-year mortality was 385/746 (51.3%) in the restrictive-fluid group versus 383/767 (49.9%) in the standard-fluid group, absolute risk difference 1.5%-points [99% confidence interval (CI) − 4.8 to 7.8]. Mean differences were 0.00 (99% CI − 0.06 to 0.05) for EQ-5D-5L index values, − 0.65 for EQ VAS (− 5.40 to 4.08), and − 0.14 for Mini MoCA (− 1.59 to 1.14) for the restrictive-fluid group versus the standard-fluid group. The results for survivors only were similar in both groups. Conclusions Among adult ICU patients with septic shock, restrictive versus standard IV fluid therapy resulted in similar survival, HRQoL, and cognitive function at 1 year, but clinically important differences could not be ruled out.